Please ensure Javascript is enabled for purposes of website accessibility

Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today

By Brian Orelli, PhD – Feb 8, 2017 at 1:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the start of a new clinical trial.

What happened

Cellect Biotechnology (APOP) stock is up nearly 30% at 12:06 p.m. EST after the company announced that it treated the first patient in the biotech's phase 1/2 trial, dubbed ApoGraft01, testing its stem cell technology ApoGraft in patients with blood cancer.

So what

Treating the first patient shouldn't have come as much of a surprise to investors. In November, the company said the Israeli Ministry of Health had given its approval to begin the trial. Perhaps investors are just really happy that the trial is finally starting. Also keep in mind that Cellect Biotechnology has a fairly low market cap, so the relative increase in valuation wasn't that much.

Stem cells

Image source: Getty Images.

Cellect Biotechnology's ApoGraft attempts to better select stem cells to help prevent graft-versus-host disease (GvHD), which occurs in 25% to 50% of recipients of allogeneic stem cell transplantation. GvHD happens when the donated stem cells produce immune cells that start mistakenly attacking the patients' normal cells because they see it as foreign. GvHD leads to 15% of the deaths that occur after allogeneic stem cell transplantation.

Now what

ApoGraft01 will enroll 12 patients, so it shouldn't take too long for Cellect Biotechnology to fully enroll the trial. Before data from that trial reads out, investors will get results from a trial testing ApoGraft in healthy volunteers by the end of the first quarter.

While Cellect Biotechnology is progressing, investors should proceed with caution given the biotech's precarious capital situation. At the end of September, Cellect Biotechnology had just $9.4 million in cash and cash equivalents on the books. The company may be able to raise additional capital, but most biotechs raise capital through secondary offerings, diluting shareholders' equity in the process.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cellect Biotechnology Ltd. Stock Quote
Cellect Biotechnology Ltd.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.